CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY DEPARTMENT OF PESTICIDE REGULATION MEDICAL TOXICOLOGY BRANCH

SUMMARY OF TOXICOLOGY DATA 4,4-DIMETHYLOXAZOLIDINE AND 3,4,4-TRIMETHYLOXAZOLIDINE

Chemical Code # 002156 and 002157, DPN # 50262 SB 950 # 259 and 926 February 23, 2005

I. DATA GAP STATUS

Chronic toxicity, rat: Data gap, no study submitted.

Subchronic, rat (dermal)

Data gap, inadequate study, no adverse systemic effect

indicated

Chronic toxicity, dog: Data gap, no study submitted

Oncogenicity, rat: Data gap, no study submitted

Oncogenicity, mouse: Data gap, no study submitted

Reproduction, rat: Data gap, no study submitted.

Teratology, rat: Data gap, no study submitted.

Teratology, rabbit: No data gap, no adverse effect.

Gene mutation: No data gap, possible adverse effect

Chromosome effects: No data gap, possible adverse effect

DNA damage No data gap, no adverse effect

Neurotoxicity: Not required at this time

Toxicology one-liners are attached.

The registration for 3,4,4-trimethyloxazolidine has been withdrawn from California.

All record numbers through 114772 were examined.

Bold face indicates a possible adverse effect.

File name: T050223

Original: Kishiyama and Gee, February 23, 2005

There is a US EPA "Reregistration Eligibility Decision (RED)" on 4,4-Dimethyloxazolidine, dated August 1996. It rapidly hydrolyzes to formaldehyde and 2-amino-2-methyl-1-propanol.

4,4-Dimethyloxazolidine is an antimicrobial with non-food registrations only. There is no anticipated dietary exposure.

^{**} indicates an acceptable study.

II. TOXICOLOGY ONE-LINERS AND CONCLUSIONS

These pages contain summaries only. Individual worksheets may contain additional effects.

COMBINED, RAT

No study submitted

CHRONIC TOXICITY, RAT

Subchronic:

015 114772 Pennisi, S. C. "Phase 3 Reformat of MRID No. 252955: Thirteen Week Subchronic Dermal Toxicity Study in Rats Amine CS-1135." (Avon Products, Inc., Study Project Code AT0156, April 24, 1980.) Amine CS-1135, 78% ai, was administered at doses of 0 (50-50 ethanol-water), 1.95, 19.5, and 195 mg ai/kg body weight, 5 days/week for a total of 67-68 days to 15 Sprague-Dawley rats/sex/group. Skin irritation was slight for the mid-dose group, but increased in incidence and severity for the high dose group. Dermal/systemic NOEL = 19.5 mg/kg/day. Reduced bodyweight gain for high dose females was attributed directly to skin irritation. Blood and serum changes were reported as not toxicologically significant. Note: This study was judged acceptable by the U.S.E.P.A. UNACCEPTABLE (insufficient information). Not upgradeable (no ophthalmology). (Kishiyama and Gee, 10/29/04).

The RED of US EPA lists another dermal study in the rat, which is not on file with the Department. The citation is: Allan, S., et al. (1994) "Thirteen-week dermal toxicity study in rats with 4,4-dimethyloxazolidine: Final report." Lab. No. TCC/3/931087:94/192A1. Huntingdon Research Center. The doses were 0, 1, 30 and 100 mg/kg/day, occluded for 6 hours, 5 days/week for 4 or 13 weeks. According to the summary in the RED, the systemic NOEL was > 100 mg/kg/day. The dermal NOEL was 1 mg/kg/day based on microscopically observed changes in the treated skin (inflammation, ulceration, acanthosis). (Gee, 10/29/04)

CHRONIC TOXICITY, DOG

No study submitted

ONCOGENICITY, RAT

No study submitted

ONCOGENICITY, MOUSE

No study submitted

REPRODUCTION, RAT

No study submitted

TERATOLOGY, RAT

TERATOLOGY, RABBIT

** 014 114771 Arnold, K. S. "Dermal Teratology Study in Rabbits." (International Research and Development Corporation, IRDC 509-002, February 13, 1986.) OxabanTM -A, purity not stated but assumed 78%, specific gravity 0.9832, was administered neat to the skin (shaven backs) of 16 mated New Zealand White female rabbits/group at doses of 0 (deionized water), 30, 100, and 300 mg/kg/day for 6 hours/day on gestation days 7 through 19. Volumes were 0.0305, 0.1017 and 0.3051 ml/kg of undiluted material as supplied. Thrashing in the cage immediately after dosing occurred in 1, 5 and 4 does treated with 30, 100 and 300 mg/kg, respectively, on days 18 and/or 19 of gestation. Maternal NOEL <30 mg/kg/day (skin irritation). Developmental NOEL >300 mg/kg/day. ACCEPTABLE (Kishiyama and Gee, 10/29/04).

GENE MUTATION

** 004 - 028365 "L5178Y TK +/- Mouse Lymphoma Mutagenesis Assay" (Kirby, P. E., study director, Microbiological Associates, Bethesda, MD, Study No. T1840-701001, January 24, 1983.) 4,4-Dimethyloxazolidine (aqueous solution, lot 6178-29) was assayed at 16 concentrations ranging from 0.0024 to 0.032 μl/ml without metabolic activation and from 0.01 to 0.1 μl/ml with S9 Mix for mutagenicity using mouse lymphoma cells. Exposure was for 4 hours followed by a 2-day expression period. There were triplicate plates for mutagenicity and for viability from a single culture per concentration. The five highest concentrations without activation (0.01 to 0.032 :l/ml) and the two highest activated concentrations (0.075 and 0.1 :l/ml) induced mutation frequencies that were significantly higher than solvent controls. Positive controls were functional. Possible adverse effect. ACCEPTABLE (with minor variances). (D. Shimer and J. Wong, 6/27/85).

002 982994 Ames Mutagenicity Test of Bioban CS-1135 on *Salmonella typhimurium* (1 Page summary). Angus Chemical Company. Summary states that the study was negative for CS-1135. UNACCEPTABLE (insufficient information/no data). (D. Shimer and J. Wong, 6/27/85).

Haworth, S. R., Lawlor, T. E., Smith, J. K. et al. (1980) "Salmonella/mammalian-microsome plate incorporation mutagenesis assay." Study no. 035-201-430-1. Unpublished study prepared by EG&G Mason Research Institute, submitted by International Minerals and Chemical Corp., Terre Haute, Ind. Not on file.

Haworth, S. R., Lawlor, T. E., Smith, J. K. et al. (1980) "Salmonella/mammalian-microsome plate incorporation mutagenesis assay." Study no. 035-201-431-1. Unpublished study prepared by EG&G Mason Research Institute, submitted by International Minerals and Chemical Corp., Terre Haute, Ind. Not on file.

CHROMOSOME EFFECTS

(Thilagar, A., study director, Microbiological Associates Bethesda, MD Study No. T1840.338, December 21, 1982.) 4,4-Dimethyloxazolidine solution (lot 6178-29) was assayed at concentrations of 0 (water), and 0.02 to 0.15 µl/ml without activation and 0.07 to 0.5 µl/ml with metabolic activation (S9 Mix) using Chinese hamster (CHO) ovary cells. Exposure was for 4 hours followed by a 16-hour further incubation. Mitotic cells were collected by mitotic shake-off for evaluation. Fifty metaphase cells per concentration were scored from three concentrations with and without activation. Both with and without activation, the % of cells with aberrations and the number per cell were significantly increased. **Possible adverse effect**. ACCEPTABLE (with minor variances). (D. Shimer and J. Wong, 6/27/85).

Asquith, J. (1984) Cytogenic analysis of the bone marrow of rats treated with HP 60/83 (Oxaban-A or Bioban CS-1135." Lab project no SR374, prepared by Toxicol Laboratories, Ltd. Not on file.

DNA DAMAGE

** 014 114770 Enninga, I.C. "Evaluation of the DNA Repair Inducing Ability of OxabanTM -A (BiobanTMCS-1135)." (RCC NOTOX, The Netherlands, RCC Project No. 020327, February 13, 1990.) OxabanTM, purity 78%, was evaluated for DNA repair inducing ability at concentrations of 0, 10, 33, 100, 333, 1000, 3300 and 5000 µg/ml in Experiment #1 and at 0, 1.0, 3.3, 10, 33, 100, 333 and 1000 ug/ml in Experiment #2, using male Wistar rat hepatocytes. exposed for 18 hours with triplicate coverslips per concentration. The highest concentrations were toxic in both experiments (5000 and 1000 ug/ml). Unscheduled DNA synthesis was measured by autoradiography with 50 cells scored per coverslip. No evidence of mutagenic activity was reported. ACCEPTABLE. (Kishiyama and Gee. 10/29/04).

The US EPA RED lists another study that is not on file with the Department. The citation is: Enniga, I. (1989) "Micronucleus test in bone marrow cells of the mouse with Oxaban-A (Bioban CS-1135)." Lab no. 0112522, RCC Notox. The summary in the RED stated that the test was negative at 500 mg/kg but the PCE/NCE ratio was decreased at 72 hours. (Gee, 10/29/04)

NEUROTOXICITY

Not required at this time.